TARGETgene: A Tool for Identification of Potential Therapeutic Targets in Cancer

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Wu, Chia Chin ^a   D'Argenio, David ^b   Asgharzadeh, Shahab ^b   Triche, Timothy ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALSTERPAULLONE; ARSENIC TRIOXIDE; CELECOXIB; DASATINIB; FLAVOPIRIDOL; GELDANAMYCIN; LAPATINIB; LITHIUM; MELATONIN; OLOMOUCINE; RAZOXANE; STAUROSPORINE; TRASTUZUMAB; VORINOSTAT;

ARTICLE; BREAST CANCER; COLON CANCER; COMPUTER INTERFACE; COMPUTER PROGRAM; DRUG TARGETING; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE MAPPING; GENE MUTATION; GENE TARGETING; GENETIC ANALYSIS; HUMAN; LUNG ADENOCARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MOLECULARLY TARGETED THERAPY; RNA INTERFERENCE; TUMOR GENE; VALIDATION PROCESS;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CHROMOSOME MAPPING; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; DRUG DESIGN; GENOME, HUMAN; GENOMICS; HUMANS; NEOPLASMS; PHENOTYPE; PROTEOMICS; RNA INTERFERENCE; ROC CURVE; SOFTWARE; SYSTEMS BIOLOGY;

EID: 84865646638     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043305     Document Type: Article

References (73)

1. Vogelstein B, Kinzler KW, (2004) Cancer genes and pathways they control. Nature Medicine 10 (8): 789-799.
2. Stears RL, Martinsky T, Schena M, (2003) Trends in microarray analysis. Nature Medicine 9: 140-145.
3. Rual JF, Venkatesan K, Hao T, Hirozane-Kishikawa T, Dricot A, et al. (2005) Towards a proteome-scale map of the human protein-protein interaction network. Nature 437: 1173-1178.
4. Stelzl U, Worm U, Lalowski M, Haenig C, Brembeck FH, et al. (2005) A human protein-protein interaction network: a resource for annotating the proteome. Cell 122 (6): 957-968.
5. Loging W, Harland L, Williams-Jones B, (2007) High-throughput electronic biology: mining information for drug discovery. Nature Reviews Drug Discovery 6 (6): 220-230.
6. Jansen R, Yu H, Greenbaum D, Kluger Y, Krogan NJ, et al. (2003) A Bayesian network approach for predicting protein-protein interactions from genomic data. Science 302: 449-453.
7. Troyanskaya OG, Dolinski K, Owen AB, Altman RB, Botstein D, et al. (2003) A Bayesian framework for combining heterogeneous data sources for gene function prediction (in Saccharomyces cerevisiae). Proc Natl Acad Sci 100 (14): 8348-8353.
8. Lee I, Date SV, Adai AT, Marcotte EM, (2004) A probabilistic functional network of yeast genes. Science 306: 1555-1558.
9. Lee I, Lehner B, Crombie C, Wong W, Fraser AG, et al. (2008) A single gene network accurately predicts phenotypic effects of gene perturbation in Caenorhabditis elegans. Nature Genetics 40: 181-188.
10. Rhodes DR, Tomlins SA, Varambally S, Mahavisno V, Barrette T, et al. (2005) Probabilistic model of the human protein-protein interaction network. Nat Biotechnol 23: 951-959.
11. Wu CC, Asgharzadeh S, Triche TJ, D'Argenio DZ, (2010) Prediction of human functional genetic networks from heterogeneous data using RVM-based ensemble learning. Bioinformatics 26 (6): 807-813.
12. Barabási AL, Gulbahce N, Loscalzo J, (2011) Network medicine: a network-based approach to human disease. Nature Reviews Genetics 12: 56-68.
13. Torkamani A, Schork NJ, (2009) Identification of rare cancer driver mutations by network reconstruction. Genome Research 19 (9): 1570-1578.
14. Wu X, Jiang R, Zhang MQ, Li S, (2008) Network-based global inference of human disease genes. Mol Syst Biol 4: 189.
15. Hanahan D, Weinberg RA, (2000) The hallmarks of cancer. Cell 100 (1): 57-70.
16. Cui Q, Ma Y, Jaramillo M, Bari H, Awan A, et al. (2007) A map of human cancer signaling. Mol Syst Biol 3: 152.
17. Taylor IW, Linding R, Warde-Farley D, Liu Y, Pesquita C, et al. (2009) Dynamic modularity in protein interaction networks predicts breast cancer outcome. Nat Biotechnol 27 (2): 199-204.
18. Knox C, Law V, Jewison T, Liu P, Ly S, et al. (2011) DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res 39 (Database issue): D1035-1041.
19. Hodge AE, Altman RB, Klein TE, (2007) The PharmGKB: integration, aggregation, and annotation of pharmacogenomic data and knowledge. Clin Pharmacol Ther 81 (1): 21-24.
20. Zhu F, Han B, Kumar P, Liu X, Ma X, et al. (2010) Update of TTD: Therapeutic target database. Nucleic Acids Res 38 (Database issue): D787-791.
21. Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, et al. (2007) NCBI GEO: Mining tens of millions of expression profiles databases and tools update. Nucleic Acids Res 35: D760-765.
22. Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, et al. (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314 (5797): 268-274.
23. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, et al. (2007) The genomic landscapes of human breast and colorectal cancers. Science 318 (5853): 1108-1113.
24. Higgins ME, Claremont M, Major JE, Sander C, Lash AE, (2006) CancerGenes: a gene selection resource for cancer genome projects. Nucleic Acids Res 35 (Database issue): D721-726.
25. Iorns E, Lord CJ, Turner N, Ashworth A, (2007) Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov 6 (7): 556-568.
26. Gilsdorf M, Horn T, Arziman Z, Pelz O, Kiner E, et al. (2009) GenomeRNAi: a database for cell-based RNAi phenotypes. 2009 update. Nucleic Acids Res 38 (Database issue): D448-452.
27. Rabinovsky R, Pochanard P, McNear C, Brachmann SM, Duke-Cohan JS, et al. (2009) p85 associates with unphosphorylated PTEN and the PTEN-associated complex. Mol Cell Biol 29 (19): 5377-5388.
28. Srougi MC, Burridge K, (2011) The nuclear guanine nucleotide exchange factors Ect2 and Net1 regulate RhoB-mediated cell death after DNA damage. PLoS One 6 (2): e17108.
29. Wang Q, Lu J, Yang C, Wang X, Cheng L, et al. (2002) CASK and its target gene Reelin were co-upregulated in human esophageal carcinoma. Cancer Lett 179 (1): 71-77.
30. Liu H, Di Cunto F, Imarisio S, Reid LM, (2003) Citron kinase is a cell cycle-dependent, nuclear protein required for G2/M transition of hepatocytes. J Biol Chem 278 (4): 2541-2548.
31. Eden E, Navon R, Steinfeld I, Lipson D, Yakhini Z, (2009) GOrilla: A Tool for discovery and visualization of enriched GO terms in ranked gene Lists. BMC Bioinformatics 10: 48.
32. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144 (5): 646-674.
33. Shawver LK, Slamon D, Ullrich A, (2002) Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1 (2): 117-123.
34. Sawyers C, (2004) Targeted cancer therapy. Nature 432 (7015): 294-297.
35. Krause DS, Van Etten RA, (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353 (2): 172-187.
36. Frank DA, (2009) Targeting transcription factors for cancer therapy. IDrugs 12 (1): 29-33.
37. Seet BT, Dikic I, Zhou MM, Pawson T, (2006) Reading protein modifications with interaction domains. Nat Rev Mol Cell Biol 7 (7): 473-483.
38. Mills E, Wu P, Seely D, Guyatt G, (2005) Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. J Pineal Res 39 (4): 360-366.
39. Navara KJ, Nelson RJ, (2007) The dark side of light at night: physiological, epidemiological, and ecological consequences. J Pineal Res 43 (3): 215-224.
40. Buras RR, Schumaker LM, Davoodi F, Brenner RV, Shabahang M, et al. (1994) Vitamin D receptors in breast cancer cells. Breast Cancer Res Treat 31: 191-202.
41. Friedrich M, Axt-Fliedner R, Villena-Heinsen C, Tilgen W, Schmidt W, et al. (2002) Analysis of vitamin D-receptor (VDR) and retinoid X-receptor alpha in breast cancer. Histochem J 34: 35-40.
42. Diesing D, Cordes T, Fischer D, Diedrich K, Friedrich M, (2006) Vitamin D-metabolism in the human breast cancer cell line MCF-7. Anticancer Res 26 (4A): 2755-2759.
43. Costa JL, Eijk PP, van de Wiel MA, ten Berge D, Schmitt F, et al. (2009) Anti-proliferative action of vitamin D in MCF7 is still active after siRNA-VDR knock-down. BMC Genomics 10: 499.
44. Köstner K, Denzer N, Müller CS, Klein R, Tilgen W, et al. (2009) The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res 29 (9): 3511-3536.
45. Fornier MN, Morris PG, Abbruzzi A, D'Andrea G, Gilewski T, et al. (2011) A phase I study of Dasatinib and weekly Paclitaxel for metastatic breast cancer. Ann Oncol 22 (12): 2575-2581.
46. Herold CI, Chadaram V, Peterson BL, Marcom PK, Hopkins J, et al. (2011) Phase II trial of Dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing. Clin Cancer Res 17 (18): 6061-6070.
47. Fujii T, Yokoyama G, Takahashi H, Toh U, Kage M, et al. (2008) Preclinical and clinical studies of novel breast cancer drugs targeting molecules involved in protein kinase C signaling, the putative metastasis-suppressor gene Cap43 and the Y-box binding protein-1. Curr Med Chem 15 (6): 528-537.
48. Fornier MN, Rathkopf D, Shah M, Patil S, O'Reilly E, et al. (2007) Phase I dose-finding study of weekly Docetaxel followed by Flavopiridol for patients with advanced solid tumors. Clin Cancer Res 13 (19): 5841-5846.
49. Witters LM, Myers A, Lipton A, (2004) Combining Flavopiridol with various signal transduction inhibitors. Oncol Rep 11 (3): 693-698.
50. Hawkins W, Mitchell C, McKinstry R, Gilfor D, Starkey J, et al. (2005) Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Cancer Biol Ther 4 (11): 1275-1284.
51. Kohfeld S, Jones PG, Totzke F, Schächtele C, Kubbutat MH, et al. (2007) 1-Aryl-4,6-dihydropyrazolo[4,3-d][1]benzazepin-5(1H)-ones: a new class of antiproliferative agents with selectivity for human leukemia and breast cancer cell lines. Eur J Med Chem 42 (11-12): 1317-1324.
52. Wesierska-Gadek J, Gueorguieva M, Wojciechowski J, Horky M, (2004) Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: a comparison of the effects exerted by Roscovitine and Olomoucine. Pol J Pharmacol 56 (5): 635-641.
53. Wardley AM, Pivot X, Morales-Vasquez F, Zetina LM, de Fátima Dias Gaui M, et al. (2010) Randomized phase II trial of first-line Trastuzumab plus Docetaxel and Capecitabine compared with Trastuzumab plus Docetaxel in HER2-positive metastatic breast cancer. J Clin Oncol 28 (6): 976-83.
54. Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, et al. (2009) Trastuzumab plus Anastrozole versus Anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 27 (33): 5529-5537.
55. Frampton JE, (2009) Lapatinib: a review of its use in the treatment of HER2-overexpressing, Trastuzumab-refractory, advanced or metastatic breast cancer. Drugs 69 (15): 2125-2148.
56. Esteva FJ, Yu D, Hung MC, Hortobagyi GN, (2010) Molecular predictors of response to Trastuzumab and Lapatinib in breast cancer. Nat Rev Clin Oncol 7 (2): 98-107.
57. Gligorov J, Lotz JP, (2008) Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer. Breast Cancer Res Treat 112 Suppl 1: 53-66.
58. Farina AK, Bong YS, Feltes CM, Byers SW, (2009) Post-transcriptional regulation of cadherin-11 expression by GSK-3 and beta-catenin in prostate and breast cancer cells. PLoS One 4 (3): e4797.
59. Navara KJ, Nelson RJ, (2007) The dark side of light at night: physiological, epidemiological, and ecological consequences. J Pineal Res 43 (3): 215-224.
60. Luu TH, Morgan RJ, Leong L, Lim D, McNamara M, et al. (2008) A phase II trial of Vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res 14 (21): 7138-7142.
61. Beliakoff J, Whitesell L, (2004) Hsp90: an emerging target for breast cancer therapy. Anticancer Drugs 15 (7): 651-662.
62. Perotti C, Liu R, Parusel CT, Böcher N, Schultz J, et al. (2008) Heat shock protein-90-alpha, a prolactin-STAT5 target gene identified in breast cancer cells, is involved in apoptosis regulation. Breast Cancer Res 10 (6): R94.
63. Li X, Ding X, Adrian TE, (2004) Arsenic trioxide causes redistribution of cell cycle, caspase activation, and GADD expression in human colonic, breast, and pancreatic cancer cells. Cancer Invest 22 (3): 389-400.
64. Ye J, Li A, Liu Q, Wang X, Zhou J, (2005) Inhibition of mitogen-activated protein kinase kinase enhances apoptosis induced by arsenic trioxide in human breast cancer MCF-7 cells. Clin Exp Pharmacol Physiol 32 (12): 1042-1048.
65. Meyerson M, Gabriel S, Getz G, (2010) Advances in understanding cancer genomes through second-generation sequencing. Nature Reviews Genetics 11: 685-696.
66. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, et al. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455 (7216): 1069-1075.
67. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321 (5897): 1801-1806.
68. The Cancer Genome Atlas Research Network (TCGA) (2008) Comprehensive genom-ic characterization defines human glioblastoma genes and core pathways. Nature 455 (7216): 1061-1068.
69. Cerami E, Demir E, Schultz N, Taylor BS, Sander C, (2010) Automated network analysis identifies core pathways in glioblastoma. PLoS One 5 (2): e8918.
70. Hopkins AL, Groom CR, (2002) The druggable genome. Nat Rev Drug Discov 1 (9): 727-730.
71. Russ AP, Lampel S, (2005) The druggable genome: an update. Drug Discov Today 10 (23-24): 1607-1610.
72. Lee SK, Kumar P, (2009) Conditional RNAi: towards a silent gene therapy. Adv Drug Deliv Rev 61 (7-8): 650-664.
73. Yu H, Kim PM, Sprecher E, Trifonov V, Gerstein M, (2007) The importance of bottlenecks in protein networks: correlation with gene essentiality and expression dynamics,. PLoS Comput Biol 3 (4): e59.